“ptose Biosciences Inc. (APTO) (APS.TO) (Aptose or the Company), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that the Food and Drug Administration (FDA), following a voluntary suspension of dosing b
“Ending a months-long saga of acrimony and legal wrangling, Horizon Pharma ($HZNP) is walking away from its hostile effort to acquire Depomed ($DEPO), thwarted by a judge's ruling. Horizon had hoped to buy Depomed for $33 a share and spent months pressuring management and agitating for a special s
“Merck ($MRK), the last Big Pharma standing in CETP inhibition, is pressing forward with a huge cardiovascular trial after getting the green light from its independent advisers, stepping over the scattered failures of similar projects in hopes of hitting upon a blockbuster. The drug, anacetrapib,
“Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of €19.4M ($21.7M). Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substant
“Israeli drug developer Protalix BioTherapeutics ($PLX) is backing away from its sole approved drug, selling the majority rights to partner Pfizer ($PFE) and pledging to invest the proceeds in its pipeline.”
“Biogen's 6-mg dose of its closely watched Alzheimer's drug aducanumab failed to deliver what the Big Biotech and anxious analysts were hoping to see, falling short of clinical significance on two key measures of efficacy that would have pointed toward a clear path ahead in a pivotal study. And th
“Eli Lilly ($LLY) offered long-term evidence to show that its amyloid-busting drug solanezumab has a distinct impact on Alzheimer's disease among early-stage patients, pointing to a delayed-start 3.5-year extension study, with a group of patients from the original placebo arm continuing to lag rig
FDA hits Cellectis’ off-the-shelf CAR-T program with clinical hold after first patient treated in phase 1 trial dies
Takeda joins CAR-T chasing pack with Noile-Immune alliance
Pierre Fabre buys up Igenica preclinical I-O meds
Debiopharm buys ImmunoGen ADC to grow cancer pipeline
Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection
Cel-Sci, in trying to escape clinical hold, creates new problems for Multikine R&D program at the FDA
Poxel shares jump 40% after diabetes trial hits primary goal
Zafgen starts comeback with first data on replacement weight-loss drug
Takeda joins Celgene on M2Gen’s clinical and molecular cancer data sharing program
AstraZeneca bags FDA OK on gout drug lesinurad as safety doubts linger
FDA approves Zoll's wearable defibrillator for use in children
CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research
Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures
Horizon abandons its hostile pursuit of Depomed
Merck's massive cardio study keeps rolling as fallen rivals pile up
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)
Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash
Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership
UPDATED: In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study
UPDATED: Eli Lilly offers evidence of twice-failed solanezumab's impact on Alzheimer's